Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 44 points (-0.3%) at 15,836 as of Monday, Jan. 27, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 751 issues advancing vs. 2,176 declining with 155 unchanged. The Health Services industry currently sits down 2.0% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include Align Technology ( ALGN), down 6.6%, Opko Health ( OPK), down 4.7%, Grifols ( GRFS), down 2.3%, C.R. Bard ( BCR), down 1.9% and Agilent Technologies ( A), down 1.2%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. Hologic ( HOLX) is one of the companies pushing the Health Services industry lower today. As of noon trading, Hologic is down $0.33 (-1.6%) to $20.91 on light volume. Thus far, 689,010 shares of Hologic exchanged hands as compared to its average daily volume of 4.4 million shares. The stock has ranged in price between $20.82-$21.30 after having opened the day at $21.26 as compared to the previous trading day's close of $21.24. Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women. Hologic has a market cap of $6.0 billion and is part of the health care sector. Shares are down 5.0% year-to-date as of the close of trading on Friday. Currently there are 6 analysts that rate Hologic a buy, 1 analyst rates it a sell, and 11 rate it a hold. TheStreet Ratings rates Hologic as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Hologic Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.